NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02203643,Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.,https://clinicaltrials.gov/study/NCT02203643,FORTE,ACTIVE_NOT_RECRUITING,"This study will evaluate the safety and the efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (CCyd) or lenalidomide and dexamethasone (CRd) followed by autologous transplantation ASCT or 12 cycles of carfilzomib combined with dexamethasone and lenalidomide for patients eligible for ASCT with newly diagnosed multiple myeloma. As a secondary endpoint this study will evaluate the best maintenance treatment between lenalidomide and lenalidomide combined with carfilzomib.

Four hundred seventy-seven patients, males and females aged \> 18 years, enrolled in several sites, will take part in this study.

The duration of the study is approximately 5 years.",NO,MULTIPLE MYELOMA (MM),DRUG: Carfilzomib|DRUG: Cyclophosphamide|DRUG: Lenalidomide|DRUG: Dexamethasone,"Efficacy in term of at least Very Good Partial Response (VGPR), The efficacy, in term of at least VGPR, of the combination of carfilzomib, dexamethasone with cyclophosphamide or lenalidomide after 4 cycles of induction treatment in newly diagnosed MM patients eligible for ASCT., Up to 2 years","sCR rate, the stringent complete response (sCR) rate in the 3 arms after complete primary therapy (induction, ASCT and consolidation for the transplant arms and after 12 cycles in the long treatment arm) in an explorative manner., up to 1 year|Safety as incidence of grade 3/4 adverse events, the safety in the 3 induction/consolidation arms and in the 2 maintenance arms., Up to 3 years|Survival, the survival in the 3 induction/consolidation arms and in the 2 maintenance arms., Up to 5 years|Correlation between tumor response and outcome with baseline prognostic factors., up to 5 years|Minimal Residual Disease (MRD), Minimal Residual Disease, up to 5 years|Survival after relapse, the survival after relapse, up to 7 years",,Mario Boccadoro,,ALL,"ADULT, OLDER_ADULT",PHASE2,477,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,UNITO-MM-01 / FORTE,2015-02,2016-10,2026-03-26,2014-07-30,,2024-12-05,"IRCCS--CROB --CROB di Rionero in di Rionero in Vulture, Rionero in Vulture, 85028, Italy",
